Are the ACOSOG Z0011 Trial Findings Being Applied to Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy?

2017 ◽  
Vol 23 (5) ◽  
pp. 554-562 ◽  
Author(s):  
Olga Kantor ◽  
Catherine Pesce ◽  
Erik Liederbach ◽  
Chi-Hsiung Wang ◽  
David J. Winchester ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Acosog Z0011 ◽  
Z0011 Trial

scholarly journals Eligibility for ACOSOG Z0011 Trial and Results on a Cohort of 3546 Breast Cancer Patients with Micro or Macro Metastases Sentinel Nodes

2020 ◽  
Vol 03 (01) ◽  
Author(s):  
Houvenaeghel G ◽  
Cohen M ◽  
Marc M ◽  
Barrou J ◽  
Lambaudie E ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Sentinel Nodes ◽  
Acosog Z0011 ◽  
Z0011 Trial

Widespread Implications of ACOSOG Z0011: Effect on Total Mastectomy Patients

2016 ◽  
Vol 82 (1) ◽  
pp. 53-58 ◽  
Author(s):  
Timothy C. Kenny ◽  
James Dove ◽  
Mohsen Shabahang ◽  
Nicole Woll ◽  
Marie Hunsinger ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Breast Conservation ◽  
Breast Cancer Surgery ◽  
Axillary Lymph ◽  
Breast Cancer Patients ◽  
Inclusion Criteria ◽  
Total Mastectomy ◽  
Acosog Z0011 ◽  
Z0011 Trial

The ACOSOG Z0011 trial demonstrated that axillary lymph node dissection (ALND) is not necessary for all breast cancer patients. Patients who underwent breast conservation surgery (BCS) or total mastectomy (TM) and met Z0011 criteria were identified and sorted into pre- and post-Z0011 cohorts. Four hundred ninety four patients had breast cancer surgery from July 2008 to February 2013. Of these, 255 were pre-Z0011 and 239 were post. Pre-Z0011, 14 patients met Z0011 inclusion criteria in BCS subgroup. ALND was performed in 10 of these patients (71%). Post-Z0011, 14 patients met inclusion criteria, only 1 received ALND (7%). The decrease in ALND rate was significant (p=0.001). Pre-Z0011, 28 patients in TM subgroup met extrapolated inclusion criteria, twenty-three of which received ALND (82%). Post-Z0011, 14 patients in TM subgroup met extrapolated criteria, five of which underwent ALND (36%). The decrease in rate of ALND was significant (p=0.005). This study demonstrates that the Z0011 trial significantly altered management of the axilla in all breast cancer patients with positive sentinel lymph nodes, not just those receiving BCS.

Sign in / Sign up

Export Citation Format

Share Document